Liao BC - Search Results

1

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

Liao BC, Bai YY, Lee JH, Lin CC, Lin SY, Lee YF, Ho CC, Shih JY, Chang YC, Yu CJ, Chih-Hsin Yang J, Yang PC. Liao BC, et al. J Formos Med Assoc. 2018 Apr;117(4):326-331. doi: 10.1016/j.jfma.2017.04.018. Epub 2017 May 9. J Formos Med Assoc. 2018. PMID: 28499641 Free article.

2

First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments.

Liao BC, Lin CC, Yang JC. Liao BC, et al. Drugs. 2013 Mar;73(4):357-69. doi: 10.1007/s40265-013-0020-8. Drugs. 2013. PMID: 23479407 Review.

3

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Liao BC, Lin CC, Yang JC. Liao BC, et al. Curr Opin Oncol. 2015 Mar;27(2):94-101. doi: 10.1097/CCO.0000000000000164. Curr Opin Oncol. 2015. PMID: 25611025 Review.

4

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Liao BC, Lin CC, Shih JY, Yang JC. Liao BC, et al. Ther Adv Med Oncol. 2015 Sep;7(5):274-90. doi: 10.1177/1758834015590593. Ther Adv Med Oncol. 2015. PMID: 26327925 Free PMC article. Review.

5

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.

Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. Liao BC, et al. J Thorac Oncol. 2015 Dec;10(12):1754-61. doi: 10.1097/JTO.0000000000000669. J Thorac Oncol. 2015. PMID: 26334749 Free article.

6

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Liao BC, Lin CC, Lee JH, Yang JC. Liao BC, et al. J Biomed Sci. 2016 Dec 3;23(1):86. doi: 10.1186/s12929-016-0305-9. J Biomed Sci. 2016. PMID: 27912760 Free PMC article. Review.

7

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.

Liao BC, Lin CC, Yang JC. Liao BC, et al. Curr Oncol Rep. 2017 Jan;19(1):4. doi: 10.1007/s11912-017-0560-2. Curr Oncol Rep. 2017. PMID: 28138934 Review.

8

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

Liao BC, Lin CC, Lee JH, Yang JC. Liao BC, et al. Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11. Lung Cancer. 2017. PMID: 28676222 Review.

9

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

Liao BC, Lin CC, Yang JC. Liao BC, et al. Expert Opin Pharmacother. 2018 Jun;19(8):851-864. doi: 10.1080/14656566.2018.1472765. Epub 2018 May 22. Expert Opin Pharmacother. 2018. PMID: 29726292 Review.

10

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.

Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Lin SY, et al. Among authors: liao wy, liao bc. J Cancer. 2018 Apr 19;9(10):1813-1820. doi: 10.7150/jca.24985. eCollection 2018. J Cancer. 2018. PMID: 29805708 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters